← Back to screener

Moderna, Inc. MRNA

Rank #2200 · Nasdaq · $88.0B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
29.5
P/E
-18.7
P/B
4.60
ROE
-24.7%
Op. Margin
-61.9%
Debt Ratio
17%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -18.7x, P/B 4.60x. Ranks in the top 72% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -24.7%. Ranks in the top 85% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 17%. Ranks in the top 12% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 64.4% year over year. Ranks in the top 98% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.1B$-0.2B$-0.2B$-0.1B-206.4-307
2019$0.2B$-0.3B$-0.3B$-0.3B-130.9-129
2020$0.1B$-0.4B$-0.4B$-0.6B-306.0-75
2021$0.1B$-0.5B$-0.5B$1.5B-910.0312
2022$0.8B$-0.8B$-0.7B$1.2B-95.0896
2023$18.5B$13.3B$12.2B$2.6B72.0263
2024$19.3B$9.4B$8.4B$14.1B48.932
2025$6.8B$-4.2B$-4.7B$19.1B-61.917

← See the full screener